Lexsential assisted SOFAR’s shareholders in the transaction relating to the acquisition by Alfasigma of the entire share capital of Sofar, an Italian pharmaceutical company, active in the research, production, and marketing of drugs, medical devices, and dietary supplements – with a long-standing tradition and well known to professionals and patients- with a turnover of more than 100 million, 150 references marketed in more than 10 therapeutic areas and 300 employees worldwide.
The transaction, which was launched last August and was scheduled for completion in October 2022, was successfully completed in full compliance with the planned timeline.
The Lexsential team advising SOFAR’s shareholders was led by partners Stefano Candela and Pasquale Di Mino with support from Marta Cosi, Teresa Candela, Antonio Di Mino, Cristina Mura and Silvia Sarracino.
The M&A team worked closely with Credit Suisse and Mazars (for further information: https://www.linkedin.com/feed/update/urn:li:activity:6962421108549562368).
